ABVC BioPharma, Inc. has taken a significant step to enhance its financial stability by entering into a private placement agreement for convertible promissory notes. This move, which involves raising approximately $3.4 million, is crucial for the company as it navigates the competitive landscape of the pharmaceutical preparations industry.

On October 30, 2026, ABVC BioPharma announced that it had entered into a securities purchase agreement with accredited investors for the sale of senior convertible promissory notes totaling $4,106,060. The company will receive $3,387,500 in cash for these notes, which carry a 17.5% original issue discount and are set to mature on June 30, 2027.

The notes can be converted into shares of the company’s common stock after an eight-month period, with specific conditions attached to the conversion. Notably, the company is required to seek shareholder approval for any issuance of shares that exceeds 19.99% of its outstanding shares, as stipulated by Nasdaq Listing Rules.

Additionally, ABVC BioPharma has resolved a financial dispute with Lind Global Fund II, L.P. Through a settlement agreement, the company will pay Lind $625,000, which will fully satisfy outstanding notes and terminate related security interests. This settlement not only alleviates previous financial burdens but also allows ABVC to move forward without the constraints of prior agreements that limited its financing options.

The funds raised from the private placement will be utilized for working capital and to support the funding of ABVC’s subsidiaries. This strategic move is essential for the company as it continues to develop its pharmaceutical products and navigate the complexities of the industry.

In conjunction with these financial maneuvers, ABVC BioPharma held a special meeting of shareholders on October 28, 2026, where they voted on several proposals, including the approval of the company’s 2026 Equity Incentive Plan. The proposals received overwhelming support, with 92.83% of shareholders voting in favor of the equity plan.

As ABVC BioPharma continues to implement these strategic financial decisions, it remains focused on enhancing its operational capabilities and addressing the challenges inherent in the pharmaceutical preparations sector. The company’s proactive approach to securing funding and resolving past disputes positions it for potential growth and stability in the future.

Looking ahead, ABVC BioPharma is expected to seek shareholder approval for future equity issuances, which will be critical in maintaining its growth trajectory. The company’s efforts to strengthen its financial foundation through innovative financing solutions reflect the ongoing challenges faced by firms in the pharmaceutical industry.

For further details, the filing can be accessed under accession number 0001213900-26-114729.